In vivo PET and biodistribution studies on male mice bearing an LnCaP (AR+) xenograft showed an approximately three-times-higher tumor uptake for 18F-enzalutamide than for [18F]FDHT [43]. The gene discussed is AR; the disease is neoplasm.